Disclosure of Interests: None declared

FR0687

RELATIONSHIP BETWEEN VITAMIN D SUPPLEMENTATION AND MUSCULAR STRENGTH IN ELDEST POPULATION. A SYSTEMATIC REVIEW

Maria Betina Nishishinya1, Claudia Alejandra Pereda Testa2, Adela Cristina Cis3, Monica Solana-Tramunt4, M Guerra-Balic5, Instituto traumatológico Quiron, Barcelona, Programa de doctorado en Ciencias de la educación y el deporte de la Facultad de psicología, ciencias de la educación y de IES Blanquerna, Barcelona, Rheumatology, Barcelona, Spain; 2Hospital HLA Mediterraneo, Almería, Rheumatology, Almería, Spain; 3Hospital HLA Mediterraneo, Almería, Sport Medicine, Almería, Spain; 4Ramon Llull University, FPCEE Blanquerna, Barcelona, Department of Sports Sciences, Barcelona, Spain

Background: Sarcopenia is the loss of skeletal muscle mass, strength and function that occurs as a consequence of aging. This condition result in physical disability, which limits the capacity to walk, increases the risk of falls and osteoporotic fractures. Several studies suggested an inverse relation between 25OHd serum levels, muscular strength and physical performance in the eldest. Objectives: To evaluate if vitamin D supplementation in patients > 50 years improves muscle mass, strength and performance in older patients.

Methods: We performed a systematic review through Medline, Cochrane Library, and EMBASE. Inclusion criteria: 1) patients > 50 years old, 2) receiving treatment with vitamin D 3) muscle mass and muscle strength measurements 4) systematic reviews (SR) 5) randomized clinical trials (RCT) 6) Papers written in English or Spanish.

Results: Five studies were included (4 SR and 1 RCT), n patients ranged from 121 to 5615. Patients mean age oscillated between 58-88 years, receiving variable vitamin D dose. Follow-up period fluctuated from 6 to 12 months.

<table>
<thead>
<tr>
<th>Author</th>
<th>N clinical studies/patients</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beaudart</td>
<td>N=30(CS)</td>
<td>Significant increment in patients with 25OHd &lt; 30 nmol/L and &gt; 65 years.</td>
</tr>
<tr>
<td>2014</td>
<td>n=5.615</td>
<td></td>
</tr>
<tr>
<td>SR</td>
<td>N=13(CS)</td>
<td>Significant improvement with vitamin D supplementation</td>
</tr>
<tr>
<td>n=2.268</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SR</td>
<td>n=2.268</td>
<td></td>
</tr>
<tr>
<td>Mut</td>
<td>N=13(CS)</td>
<td>Significant improvement with vitamin D supplementation</td>
</tr>
<tr>
<td>n=2.268</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SR</td>
<td>n=2.268</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>1-Postural balance reduction DME -0.20 (IC95% -0.39 a -0.01,P=0.04, I2 = 0%)</td>
<td></td>
</tr>
<tr>
<td>2-Reduction in time to finish the test TUG -0.19 (IC95% -0.35 a -0.02, P =0.03, I2 = 0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beaudart</td>
<td>N=2 (CS)</td>
<td>No additional effect of vitamin D, except for TUG (n=1)</td>
</tr>
<tr>
<td>2017</td>
<td>n=121</td>
<td></td>
</tr>
<tr>
<td>SR</td>
<td>N=17(CS)</td>
<td>Patients with serum 25(OH)D &lt;25 nmol/L, caused</td>
</tr>
<tr>
<td>n=5.072</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stockton</td>
<td>n=5.072</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>significant improvement in hip muscle strength with vitamin D supplementation (DME 3.52, IC95% 2.18, 4.85,(n=2)</td>
<td></td>
</tr>
<tr>
<td>SR</td>
<td>n=5.072</td>
<td></td>
</tr>
<tr>
<td>Ganguzza</td>
<td>N=160</td>
<td>Significant increment in vitamin D group.</td>
</tr>
<tr>
<td>2015</td>
<td>Muscular strength (chain test) 25.3% (p &lt;0.0001)</td>
<td></td>
</tr>
<tr>
<td>RCT</td>
<td>n=160</td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: • Vitamin D supplementation in patients > 65 years with inadequate 25OHD serum levels, improve muscular strength.
• There were no benefits in muscle mass or muscular performance.

REFERENCES:

Disclosure of Interests: None declared

FR0687

NEUROMYELITIS SPECTRUM DISORDERS ASSOCIATED WITH AUTOIMMUNE DISEASES: DIFFERENCES IN CLINICAL CHARACTERISTICS AND MRI FINDINGS

Milena Rodríguez Alvarez1, Manjeet Bhamra2, Vinodkumar Velayuthan3, Fernando, Cuscuta4, Latoya Freeman1, Su Yien Chia5, Joshy Pathrapalam6, Naureen Kabani7, Kristaq Koci2, Alexandre Kreps6, Justin Levinson9, Sophia Francis7, Steve Xie1, Helen Valsamis1, Abhimanyu Amarnani1, David Ozer7, Samir Akabie7, Yoacov, Anziska, Isabel Mcltanne7, 1SUNY Downstate Medical Center, Medicine, BROOKLYN, United States of America; 2Samaritan Medical Center, Neurology, Dallas, United States of America; 3Temple University Hospital, Philadelphia, United States of America; 4Sheba Medical Center, Tel Aviv, Israel

Background: Neuromyelitis Optica Spectrum disorders (NMOSD) is a rare autoimmune disease characterized by optic neuritis (ON) and/or longitudinal extensive transverse myelitis (LETM). It is commonly associated with other autoimmune diseases (OAD). Recent reports suggested racial differences in clinical phenotype and presentation of NMOSD. However, data on Black population is scarce. Objectives: We aim to characterize, in our largely Black population, the clinical, laboratory and radiologic features of patients with NMOSD and OAD. We also aim to ascertain differences in clinical presentation between NMOSD patients with and without OAD.

Methods: In a retrospective analysis, patients ≥ 18 years of age with a confirmed diagnosis of NMOSD as per the International Panel for NMOSD Diagnosis Criteria, seen at 2 NYU urban hospitals from 1/2005 to 4/2017 were identified. Demographic, clinical, and laboratory data were extracted together with expanded disability status scales (EDSS) and imaging studies. Brain magnetic resonance imaging (MRI) was reviewed by a neuro-radiologist who applied the NMOSD Radiological criteria to identify typical findings of the disease.

Results: Forty-one patients fulfilled NMOSD criteria. 85.4% were women with a mean age of 44.7±2.03 years. 82.9% of the patients were Black and 34.1% (14/41) had an associated OAD. Systemic lupus erythematosus (SLE) was the most common OAD present prior to NMOSD diagnosis, followed by thyroid disease and Sjogren syndrome. Aquaporin 4 immunoglobulin G (AQP4IgG) was positive in 82.9% of the entire cohort and in 76.9% (10/13) of patients with NMOSD and OAD. Hypertension (33.3% vs. 15.3%), and cardiovascular disease (13.3% vs. 4%) were more frequent in NMOSD with OAD, compared with the NMOSD only group. On initial presentation of the NMOSD only group, visual changes (40% vs. 26.5%) and ON (38.4% vs. 20%)were predominant. In the initial presentation of NMOSD with OAD group, sensory loss (78.5% vs. 57.7%), acute myelitis (40% vs. 23.1%), and elevated C reactive protein (CRP) (20.85±11.2 vs. 3.2±1.85mg/dL) were more frequent. Disability scores (EDSS) were 5.5 for each group. Brain MRI revealed lesions affecting corpus callosum in a marble pattern, (21.4% vs. 13.6%), the hemispheres in a spindle like pattern(33%/vs 22%), the dorsal medulla (50% vs. 39.1%), the area postrema (38.5% vs. 27.3%) and the pons (21.4% vs. 13.4) for NMOSD with OAD and without respectively. LETM with predilection for the thoracic region was (66.7% vs 54.5%), cord edema (69.2% vs. 40.9%) and gadolinium enhancement (69.2% vs. 59.1%) for NMOSD with OAD and NMOSD only patients respectively. Conclusion: AQP4IgG-positivity was observed in most of the cases in our predominantly Black NMOSD population. Over a third of the NMOSD patients had OAD. SLE was the most commonly reported. NMOSD with OAD patients tended to present with sensory loss, acute myelitis, and elevated CRP, while in NMOSD without OAD presented more with visual changes and ON. The NMOSD with OAD group had more MRI lesions involving corpus callosum, hemispheres, brainstem and LETM, compared to those with NMOSD only group.

REFERENCES:

Disclosure of Interests: None declared